Here are four highlights:
1. HemaQuell is a water soluble material that is used as a tamponade to control bleeding from bone surfaces. It is based on the multi-faceted patent that the company acquired in 2009.
2. HemaQuell will be delivered in a unique patent-pending applicator that allows surgeons to directly apply the waxy product on bleeding bones.
3. The HemaQuell bone hemostasis material is completely resorbed between two and seven days and does not delay healing of bone injury.
4. Wound Management is an emerging commercial stage company with its primary products in the $5 billion worldwide advanced wound care market.
More articles on devices and implants:
Xtant Medical’s short interest falls 0.4% — 3 facts
Mazor Robotics earnings surpass estimates — 4 notes
14 things to know about NuVasive
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.